Bank of America just raised its EUR/USD forecast
CINCINNATI, OH – Chemed Corporation (NYSE:CHE), a provider of home health care services, disclosed the outcomes of its annual stockholders’ meeting held on May 19, 2025. The detailed results are based on the company’s recent SEC 8-K filing.
At the meeting, all nominated directors were elected to the Board with a significant majority of votes. The directors include Kevin J. McNamara, Ron DeLyons, Patrick P. Grace, Christopher J. Heaney, Thomas C. Hutton, Andrea R. Lindell, Elaine McCarthy, John M. Mount Jr., and George J. Walsh III. The votes cast for each director ranged from 10,511,691 to 12,957,467 for, with broker non-votes reported at 606,879 for each nominee. According to InvestingPro data, the company’s management has been actively buying back shares, demonstrating alignment with shareholder interests.
Additionally, the proposal to approve and adopt the Company’s 2025 Stock Incentive Plan received affirmative votes, with 11,536,322 for, 1,473,289 against, and 7,228 abstentions. Broker non-votes were not applicable to this proposal.
The appointment of PricewaterhouseCoopers LLP as the company’s independent accountants for the year ending December 31, 2024, was ratified with 13,250,853 votes for, 365,426 against, and 7,439 abstentions.
Furthermore, the company’s executive compensation program was approved on a non-binding basis with 11,039,768 votes for, 1,656,237 against, and 320,853 abstentions. Broker non-votes for this proposal totaled 606,879.
A proposal to reduce the stockholder threshold for calling a special meeting to 10% was not presented at the meeting as neither the proponent nor a representative attended.
The information provided in this article is based on a press release statement from the SEC filing by Chemed Corporation. Currently trading near its 52-week high, Chemed shows strong market momentum with a 9.2% year-to-date return. For deeper insights into Chemed’s financial health, valuation metrics, and expert analysis, access the comprehensive Pro Research Report available exclusively on InvestingPro, along with 10 additional ProTips and extensive financial metrics.
In other recent news, Chemed Corporation reported its first-quarter 2025 financial results, surpassing analysts’ expectations with an earnings per share (EPS) of $5.63, compared to the projected $5.51. The company also exceeded revenue forecasts, achieving $646.9 million against the anticipated $636.8 million. RBC Capital Markets responded by raising Chemed’s price target to $674.00, citing a robust first-quarter performance and a positive outlook for the Roto-Rooter business. BofA Securities maintained a Buy rating for Chemed, with a price target of $708.00, following discussions about the company’s strategies at the BofA Health Care Conference. Chemed’s VITAS Healthcare segment demonstrated strong growth, with a 15.1% increase in net revenue year-over-year. The Roto-Rooter division, however, faced challenges with a 2.4% decline in adjusted EBITDA. Analysts from RBC Capital noted that concerns over Medicare cap limitations might be overstated, as Chemed has been managing these issues strategically. Investors are keeping an eye on Chemed’s handling of the Medicare cap situation, which remains a pivotal factor in the company’s ongoing success.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.